Literature DB >> 22717311

Osteoporosis prescribing trends in primary care: a population-based retrospective cohort study.

Li Wang1, C Shawn Tracy, Rahim Moineddin, Ross E G Upshur.   

Abstract

BACKGROUND: Osteoporosis is a highly prevalent and costly disease associated with aging. Previous studies have indicated low intervention rates in primary care; however, there is little research investigating the prescribing patterns of osteoporosis medications by primary-care physicians.
METHODS: We conducted a population-based retrospective cohort study to examine trends in osteoporosis medication utilization in primary care between 1 January 2000 and 31 December 2009 in Ontario, Canada. All Ontario residents aged 65 years or older and eligible for public health coverage were included in the analysis (∼1.46 million residents in 2000, ∼1.75 million residents in 2009).
RESULTS: Analysis of 10-year data indicates a trend toward higher utilization of osteoporosis medications among elderly primary-care patients. In 2000, 100 038 unique patients were prescribed an osteoporosis medication by a family physician; by 2009, this number increased to 301 679. Age-group analyses suggest an inverted U-shaped pattern, whereby utilization rates increase with advancing age and then decline for the oldest age groups. Utilization rates were the lowest for the 100+ age group.
CONCLUSIONS: This study indicates increased utilization of osteoporosis-related medications among elderly primary-care patients over a recent 10-year time period. It is unclear whether the observed increase in utilization is due to higher rates of osteoporosis. Further research is needed to determine the appropriateness of this higher utilization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22717311     DOI: 10.1017/S1463423612000114

Source DB:  PubMed          Journal:  Prim Health Care Res Dev        ISSN: 1463-4236            Impact factor:   1.458


  7 in total

1.  Overuse and Underuse of Antiosteoporotic Treatments According to Highly Influential Osteoporosis Guidelines: A Population-Based Cross-Sectional Study in Spain.

Authors:  Gabriel Sanfélix-Gimeno; Isabel Hurtado; José Sanfélix-Genovés; Cristóbal Baixauli-Pérez; Clara L Rodríguez-Bernal; Salvador Peiró
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

2.  Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010.

Authors:  C Klop; D Gibson-Smith; P J M Elders; P M J Welsing; H G M Leufkens; N C Harvey; J W J Bijlsma; T-P van Staa; F de Vries
Journal:  Osteoporos Int       Date:  2015-05-12       Impact factor: 4.507

3.  Variation in Antiosteoporotic Drug Prescribing and Spending Across Spain. A Population-Based Ecological Cross-Sectional Study.

Authors:  Gabriel Sanfélix-Gimeno; Julián Librero-López; Gracia Modroño-Riaño; Salvador Peiró; Clara L Rodríguez-Bernal
Journal:  Front Pharmacol       Date:  2018-04-13       Impact factor: 5.810

4.  Variations in osteoporosis medication utilization. A population-based ecological cross-sectional study in the region of Valencia, Spain.

Authors:  Gabriel Sanfélix-Gimeno; María-Lirios Juliá-Sanchis; Julián Librero; Salvador Peiró; Aníbal García-Sempere
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

5.  Practice of Family Physicians in the Management of Osteoporosis Among Older Female Patients at King Abdulaziz Medical City, Riyadh, Saudi Arabia.

Authors:  Siham M AlAnazi; Amani A AlKhamali; Mohammed A AlAteeq
Journal:  Cureus       Date:  2022-02-19

6.  Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity.

Authors:  R Y van der Velde; C E Wyers; E Teesselink; P P M M Geusens; J P W van den Bergh; F de Vries; C Cooper; N C Harvey; T P van Staa
Journal:  Bone       Date:  2016-10-11       Impact factor: 4.398

Review 7.  Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.

Authors:  Ellen Wright; Peter T Schofield; Mariam Molokhia
Journal:  BMJ Open       Date:  2015-12-07       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.